Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC lessened its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 6.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,353 shares of the biotechnology company’s stock after selling 2,113 shares during the quarter. Sanctuary Advisors LLC’s holdings in Corcept Therapeutics were worth $1,312,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in Corcept Therapeutics in the third quarter valued at $25,000. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Corcept Therapeutics during the third quarter worth about $36,000. GAMMA Investing LLC lifted its holdings in shares of Corcept Therapeutics by 85.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,147 shares during the last quarter. nVerses Capital LLC boosted its position in shares of Corcept Therapeutics by 62.5% in the 2nd quarter. nVerses Capital LLC now owns 3,900 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 1,500 shares during the period. Finally, KBC Group NV boosted its position in shares of Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 496 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CORT shares. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Truist Financial lifted their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Finally, Piper Sandler increased their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Corcept Therapeutics has an average rating of “Buy” and an average price target of $65.25.

Insider Buying and Selling

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gary Charles Robb sold 11,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the transaction, the insider now owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. This represents a 32.57 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,811 shares of company stock valued at $1,341,360. Corporate insiders own 20.50% of the company’s stock.

Corcept Therapeutics Trading Up 0.5 %

Shares of Corcept Therapeutics stock opened at $51.40 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm has a market cap of $5.39 billion, a price-to-earnings ratio of 40.79 and a beta of 0.51. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $62.22. The company’s 50-day simple moving average is $53.83 and its 200-day simple moving average is $41.92.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. Corcept Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. As a group, equities research analysts anticipate that Corcept Therapeutics Incorporated will post 1.35 earnings per share for the current year.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.